Next 10 |
home / stock / ovid / ovid articles
NEW YORK, June 22, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ovid Therapeutics Inc. ("Ovid" or th...
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite surging over 200 points on Monday. The Dow traded up 0.57% to 38,807...
Shares of Ovid Therapeutics Inc (NASDAQ:OVID) dipped 65.7% to $1.1285 after Takeda’s Skyline study in Dravet syndrome missed its primary endp...
U.S. stocks traded mixed this morning, with the Dow Jones index falling more than 100 points on Monday. Following the market opening Monday, the Do...
Monday, Takeda Pharmaceutical Co Ltd (NYSE:TAK) announced topline data from its SKYLINE and SKYWAY Phase 3 studies of Soticlestat (TAK-935) for the...
Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) rose sharply in today's pre-market trading after the company announced results from its ongoi...
Alimera Sciences (NASDAQ: ALIM) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.04. This comp...
NEW YORK, May 13, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company developing medicines designed to co...
NEW YORK, April 04, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company dedicated to meaningfully improvi...
News, Short Squeeze, Breakout and More Instantly...
Ovid Therapeutics Inc. Company Name:
OVID Stock Symbol:
NASDAQ Market:
Ovid Therapeutics Inc. Website:
The Phase 1 study for OV888/GV101 capsule met its objective, demonstrating a favorable safety and tolerability profile with no serious adverse events Secondary endpoint results indicate that the target pharmacokinetic profile was achieved at the targeted clinical dose, supporting once daily d...
2024-06-18 10:30:03 ET B. Riley analyst issues BUY recommendation for OVID on June 18, 2024 09:12AM ET. The previous analyst recommendation was Buy. OVID was trading at $0.7744 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analy...
2024-06-18 07:15:06 ET BTIG analyst issues BUY recommendation for OVID on June 18, 2024 04:51AM ET. The previous analyst recommendation was Buy. OVID was trading at $0.7896 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst r...